Philip Morris International Inc. (PM) Earnings Call Transcript & Summary
July 22, 2025
Earnings Call Speaker Segments
James Bushnell
executiveThanks, operator. At this point, I'd like to pass the conference to today's speaker, James Bushnell. We put out a press release earlier today with full details about our results for the second quarter of 2025. You can find that press release on our site, PMI.com. A glossary of terms — covering the definition of smoke-free products, plus adjustments, other calculations, and reconciliations to the most directly comparable US GAAP measures for the non-GAAP financial measures mentioned in this presentation — appears in exhibit 99.2 of the company's Form 8-K dated today, and also on our investor relations website. Remarks given today include forward-looking statements and projections of future results. I point you to the forward-looking and cautionary statements disclosure in today's presentation and press release, which reviews the various factors that could cause actual results to differ materially from projections or forward-looking statements. Emmanuel Babeau, Chief Financial Officer, is with us today. Over to you, Emmanuel.
Emmanuel Babeau
executiveThanks, James, and good morning to everybody. We turned in a superb first-half set of results after yet another really robust showing during 2025's second quarter. Momentum from the combustible lineup, which brought in $4 billion of net revenues, along with better margins throughout the company, powered double-digit increases in adjusted diluted EPS on both a constant-currency and a dollar basis. Our Smoke-Free portfolio's multi-category drive picked up speed, with offtake growth stepping up in Q2 for IQOS, ZYN, and VEEV. IQOS came through as anticipated with yet another solid showing, as heated tobacco unit adjusted in-market sales climbed to plus 11.4% during Q2. That mirrors wide-ranging gains worldwide and across Europe, where markets including Italy have moved past the temporary upheaval caused by the characterizing flavor ban. ZYN then affirmed its rising path, with US consumer offtake growth speeding up markedly to plus 26% in Q2 and plus 36% during June, helped by better in-store availability. Outside the US, nicotine pouch volumes for Q2 rose plus 65% and nearly tripled in markets beyond the Nordics. On e-vapor, VEEV kept up its outstanding path, with shipments greater than doubling versus a year earlier and pushing gross margin expansion further. Turning to combustibles, even with an unanticipated swing back to slight volume decreases, the business posted solid results on both the top and bottom lines, showing the strength of its resilience model underpinned by firm pricing. We keep producing best-in-class growth throughout the P&L, with high single-digit organic first-half top line expansion and mid-teens adjusted OI growth, arriving at a margin above 41%; this top-quality outcome mirrors the rising profitability of our three smoke-free categories: scale, operating leverage, and efficiencies working together; these results give us a great foundation for yet another year of standout growth. We look for solid smoke-free momentum to carry into H2, while we account for the extraordinary H2 prior comparison, particularly on rising combustible volumes, plus some timing considerations. Given solid business fundamentals and a somewhat more favorable expected tax rate, we are lifting our adjusted diluted EPS full-year guidance to plus 13% to plus 15% growth, or plus 11.5% to plus 13.5% excluding currency. Now to our Q2 financials. We posted yet another quarter of shipment volume growth at plus 1.2% and organic top line growth at plus 6.8%, or plus 7.1% in dollar terms, reaching more than $10 billion in quarterly net revenues for the first time. Setting aside the Indonesia technical impact covered last quarter, organic net revenues rose by over plus 8%. Adjusted OI rose plus 14.9% organically, with better profitability across every category, a positive smoke-free margin mix, and continued cost efficiencies. Adjusted diluted EPS of $1.91 represents growth of plus 20%, including favorable currency variance of $0.02, which is $0.04 lower than previously guided, mainly because of intercompany transactional impact from currency volatility at period end, including on the Swiss franc. This better-than-expected EPS delivery notably mirrors solid top line momentum, positive margin evolution in our smoke-free product business, and firm combustible pricing. Putting this outstanding Q2 together with a solid first quarter, we recorded one of our strongest ever first-half performances. Overall shipment quantities rose 2.5%, while organic net revenue climbed 8.4% — roughly 10% once you set aside the technical hit from Indonesia. Solid results in both smoke-free and combustible categories pushed adjusted operating income up by about 15% on an organic basis and in USD terms alike, landing at $8 billion altogether. First-half adjusted diluted EPS advanced 17.7% at constant currency, and 16.1% when measured in dollars. Now on to shipment quantities. We posted second-quarter growth of 1.2%, and 2.5% across the first six months, powered by our smoke-free segment expanding more than 13%. Even as adjusted in-market sales growth picked up pace, Q2 HTU shipment volume rose 9.2% to 38.8 billion units, with healthy gains across Europe and Japan plus encouraging momentum in markets such as Indonesia, South Korea, and global travel retail. HTU shipments for H1 were up 10.5%, essentially tracking adjusted in-market sales growth. As I noted three months ago, our H1 shipments carry a Q1 timing benefit of roughly one billion units, which we anticipate unwinding during Q4. Once again, total e-vapor shipments expanded substantially. Cigarette volumes posted a slight decline in Q2, coming off the remarkable growth seen in recent quarters. The main causes were shrinkage in Indonesia and Turkey, where a change to regulatory requirements created supply chain disruptions. That produced a temporary loss of volume and share, along with some related inventory write-downs. We look for gradual recovery through the rest of the year, although comparisons against the prior year will probably remain under pressure. In Indonesia, notwithstanding a solid share result, an expanding illicit segment is weighing on the legal industry and on our own volumes inside it. That trend will likely carry into H2 as well. For the full year, we anticipate cigarette volumes falling about 2%, closer to the historical underlying pattern. That figure incorporates an expected 3% to 4% drop in H2 against the tough prior-year comparison I referenced, with Turkey responsible for nearly half of that decrease. It also reflects continued declines in Europe and Japan as smoke-free products keep growing strongly, plus the situation in Indonesia and Egypt, where the leading local competitor is still recovering from earlier supply constraints. As evidence of how resilient our combustible business model is, we remain focused on achieving combustible gross profit growth in H2, backed by pricing and cost savings. On smoke-free products, we expect another double-digit volume increase in H2, which includes the anticipated reversal of the H1 phasing benefit on IQOS. That said, given cigarette trends, total PMI volumes could see a slight decline in H2. Crucially, with a projected full-year gain of about 1%, we remain on track for our fifth straight year of total volume growth, just as we intend for the years ahead, as our smoke portfolio keeps fueling performance. If we look at how each category performed, the standout gross margin and operating income gains during Q2 drove really impressive results for the first half, and that was fueled by our smoke-free segment becoming more and more profitable. For H1, Smoke-Free net revenue was up 17.3% on an organic basis, hitting $8.1 billion, while gross profit rose 27% to $5.6 billion, with organic expansion of 530 basis points pushing gross margin past 70%. That sits roughly 4.5 points higher than the gross margin for combustible at the geographic mix the category currently has. Just like in 2024, this shows margins continuing to widen across all three smoke-free categories, helped in particular by the favorable mix from ZYN's accretive unit economics plus pricing on both HTUs and ZYN. The very strong IQOS gross margin improvement mirrors the potent growth and scale advantages of this big and expanding business, manufacturing efficiencies, and a favorable comparison against last year's higher device shipments, when Iluma I launched in Japan and other markets. We look for that strong margin to carry into H2, though without the year-over-year device comparison benefit, while we keep broadening Illuma Eye's footprint across markets and bonds in Indonesia. Converseable net revenues climbed 2.9%, or over 5% once you strip out the Indonesia technical impact.
Emmanuel Babeau
executiveGross profit came in 5% higher, and that lifted our margin by 140 basis points. We managed that despite the financial drag tied to what happened in Turkey. The figure also reflects a solid Q2, a period in which organic net revenue climbed 2% while gross profit was up 4.8%. What this tells us is that the combustible business model we continue to run is quite resilient, because when volume slips by a low single digit amount, that gets offset by robust pricing and efficiency gains, which together deliver growth in both top line and gross profit as time goes on. Looking at the full year, our target remains expansion of combustible gross margin, both on an organic basis and in dollar terms, even though pricing will be slower and volume softer during H2. Thanks to ongoing smoke-free gains along with a sturdy combustible business, PMI as a whole delivered 15.4% organic OI growth in H1. That pushed operating income margin up by 250 basis points, moving it past 41%. Once again, our top line growth model's three engines drove H1 net revenue growth of 8.4%: positive volumes, robust pricing, and a helpful smoke remix. Pricing contributed 5.2 points, supported by 7.7% convertible pricing plus low single digit pricing for smoke-free products when devices are excluded. Fast SFP expansion contributed a further 3.1 points through its positive mix effect. Combustible geographic mix and other items took away 2.4 points, which includes roughly 1.5 points from the Indonesia technical impact. When it came to currency, that took away 1.5 points, while deals and disposals — the Vectura divestment among them — removed an additional 0.4 points. Turning to gross margins, our first-half organic gain came to 300 basis points, or 320 basis points once currency along with acquisitions and divestitures are factored in. Pricing added 106 60 basis points, which was enough to more than counter the 60 basis point hit from cost inflation after accounting for productivity and other cost items. Excellent growth of 190 basis points came from smoke-free products, driven by the factors I noted earlier. Combustible was essentially unchanged when pricing is excluded, though the Indonesia effect is included. When you look beneath the gross profit line, we're continuing to put substantial money into growing our Smokri brand down the road, the US included, and SG and A organic growth came in at 10.6% for H1, a touch higher than net revenue growth once you strip out the Indonesia technical impact. Through our manufacturing and back office efficiency initiative, gross cost savings have now topped $500 million year to date. Halfway into our 24, 26 target period, we've already delivered more than $1.2 billion, so we're firmly on pace to reach our $2 billion goal. Taking everything together, since gross margin expansion more than made up for bigger year on year commercial investments, adjusted operating income margin expanded 290 basis points in H1. Organically, that figure was 250 basis points. During the second quarter, our organic operating income margin improved by 300 basis points, which outpaced the 200 basis point gain we saw in Q1. Turning to the smoke-free side of things: our approach across multiple product categories is driving steady expansion of the people who use our smoke-free products. We figure the legal-age population for our SFPs grew by about 5 million year over year, reaching roughly 41.5 million as of June 30. With ZYN rolling out in Ireland and Cambodia during Q2, our smoke-free portfolio is now available in 97 markets. In nearly half of those markets, we now offer a multi-category lineup — that means at least two of IQOS, ZYN and VEE are being sold to legal-age nicotine users. This slide illustrates that all three categories are now deployed across 20 markets, and we keep expanding our multi-category footprint. Regulation is a crucial catalyst for smoke-free expansion, and I am happy to share further instances of encouraging movement, including laws granting new market access for one or more SFP category throughout a number of Middle East markets; we also take note of the just-published proposal to amend the EU tobacco excise directive, which signaled the beginning of a formal legislative procedure needing unanimous consent from every member state plus later transposition into national law. A number of member states have already established frameworks for regulating and taxing smoke-free products in a way that's proportionate to risk. Until the final directive arrives, those frameworks can serve as a helpful foundation and point of reference. We do recognize the clear difference between smoke-free products and combustible ones when it comes to the proposed minimum rate. Even so, we're disappointed that nothing in the plan addresses the threat of illicit trade, which accounted for 9.2% of all cigarette consumption across the EU in 2024. Meanwhile, governments are losing over 14 billion euros in tax revenue, and many countries are dealing with serious economic pressure. At the heart of our multi-category approach is the strength of the IQOS brand and its commercial footprint. That remains the primary engine driving growth in our smoke-free portfolio. Our top priority remains driving IQOS's expansion going forward, and placing ZYN and VIV under that same structure gives us added avenues to help people shift completely from cigarettes to smoke-free products. Given that, it's especially encouraging to report that IQOS HTU adjusted in-market sales growth picked up to 11.4% during Q2, with Europe standing out as a key contributor, alongside strong momentum in Italy, our biggest market, where our commercial efforts tied to the characterizing flavor of the bond are clearly paying off. Japan likewise turned in another solid quarter of gains, while our other worldwide markets stepped up their pace as well. Even though rivals are becoming more active, we view that as a good thing for the category's expansion down the road, and we anticipate that the strong momentum on high cost will carry on through the second half. Our goal for the year remains adjusted IMS growth for HTU of plus 10% to plus 12%. Ongoing innovation in IQOS devices and consumables, paired with spending on brand equity, forms essential foundations for our expansion. The introduction of Illuma Eye technology, which is now available in more than 30 markets, is still being rolled out. The range of Livia tobacco-free consumables continues to expand, and the initial response to the test variants and flavor capsules we launched recently appears promising. Beyond that, we started rolling out a resin pack design across our main premium terrier HTUs, and we've widened our mainstream-priced Delia range, which is delivering outstanding results in places like Germany and Poland. Over in the US, the small-scale IQOS three pilots are still running and drawing a lot of attention from adult consumers. While our commercial pilot in Austin moves forward, we kicked off a second pilot in Fort Lauderdale this quarter, with more initiatives lined up in the months ahead as we get ready for the at-scale launch of IQOS Iluma, pending FDA authorization. Zeen, our second flagship premium smoke-free brand, sits atop a category that could fundamentally reshape how nicotine is consumed, delivering a substantial net benefit to global public health as more adult smokers move to smoke-free products. Globally, Q2 can shipments rose by plus 43%, and offtake picked up strongly again in the US, which I'll address in more detail later. Riding the momentum of ZYN in the US, our global rollout kept moving ahead, with Q2 international can volume climbing plus 65% year on year, or an impressive plus 179% once the Nordics are excluded. This international growth mirrors both market expansion and robust offtake gains, underpinned by growing production capacity in new geography.
Emmanuel Babeau
executiveAmong the standout results was our worldwide travel retail operation, which posted volume growth near 200% when you set aside the US along with the UK, Pakistan, Poland, South Africa, and Mexico. During our recent Europe focus event, we explained that our aim is to expand the category by converting legal aged smokers instead of drawing from the modest existing category. Worth noting too, ZIN ranks first in Mexico and South Africa, where we introduced our mostly mini dry lineup around the same time as rival brands did. In over three quarters of Zine markets, dry pouches now represent most of our pouch volumes, and we think this format fits legal aged smokers particularly well. Following further launches in Q2, ZYN has a presence in 44 markets worldwide. Liz rounds out our smoke-free trilogy. First-half shipment volumes climbed by more than double, hitting nearly 1.5 billion equivalent units, with growth that keeps getting more profitable, led by Europe, where Veeve currently ranks first in close spot position across six markets, Italy and Greece among them. Beyond Europe, we see considerable opportunity for the brand, with encouraging outcomes in varied markets like Indonesia, Canada, and Colombia, plus additional rollout plans. Rising repeat purchase rates and consumer loyalty look particularly encouraging as we aim to capitalize on our multi-category infrastructure beneath the IQOS umbrella of quality, premiumness, and superior technology; along those lines, we just introduced our newest innovation, Veeze in Prime, the Czech Republic. In Prime delivers an enhanced premium user experience featuring greater flavor intensity, a bigger cloud size, and more battery capacity with an optimized podcast profile. Europe has the most advanced multi-category consumer landscape. And today we have 30 markets offering at least two categories. Naturally, IQOS stays the primary engine of our regional performance, and I'm pleased to share that Q2 brought a meaningful acceleration in HTU adjusted in market sales growth, reaching plus 9.1%, while adjusted market share rose plus 1.2 points year on year to 10.9%. This comes during a seasonally stronger stretch for combustibles. As we detailed at our recent Europe event, IQOS enjoys a very solid brand platform throughout the region, and these results mirror our innovation and commercial initiative, including those tied to Illumai Livia and Delia; that fueled robust double digit adjusted IMS growth across markets such as Germany, Spain, Romania, Greece, and Bulgaria. One significant Q2 highlight is Italy, Europe's biggest IQOS market by volume, which posted a much-appreciated gain in both sequential and year on year growth. Apart from Poland, Austria, Estonia, and Croatia, the effect of the EU characterizing flavor ban now sits behind us. And our absolute regional growth in HTU adjusted AMS is now moving nearer to pre band labels. Though quarterly comparison from 2024 carries some volatility from flavor band dynamics, Sequential trends look quite positive, and we anticipate the rest of the year with confidence in continued strong IQOS growth. Beyond the IQOS momentum, gains from our multi-category approach show up clearly when looking at combined shipments of IQOS, ZYN, and VIV — up 13.5% during Q2, versus a 10.5% rise for heated tobacco units by themselves. Both ZYN and VIV remain at a very early stage of their development, yet they are posting remarkable growth. Those figures cover Europe as a whole, and I should add that in markets where all three brands are sold, such as Italy, Greece, Poland, and Romania, SSP volume growth runs several points higher. Over in Japan, we hit an important milestone of 10 million estimated users, and Q2 adjusted HTU share climbed 2.3 percentage points year over year to reach 31.7%, even as competition grew more intense. IQOS keeps making solid headway, with Q2 adjusted IMS rising 7.8% against the same period a year earlier, which had included the full rollout of Iluma I. As the slide shows, we managed truly outstanding growth across 23 and 24, particularly given how large the category has become — it now accounts for nearly half of total nicotine of tech volume nationwide, and over half in some cities. The high single digit expansion our business saw in H1 2025 stays quite robust and broadly matches the pattern of earlier years. We anticipate additional strong adjusted IMS growth over the rest of the year. It is encouraging that rivals are now backing the heat not burn category, and although our category share held steady sequentially at roughly 70% in Q2, our main priority is growing smoke-free products as a whole, maximizing gains for our leading offering, and bringing more smokers over. Turning to the US now. ZYN's sharp reacceleration stands out as a clear bright spot in our Q2 results and shows the brand's strength as in store availability recovers and legal edge consumers once again can reach the complete ZYN portfolio. Earlier quarters' supply limitations had held back sellout volume growth and left ZYN expanding more slowly than the category overall. Now that manufacturing capacity is in excellent shape, the rebound reached roughly plus 36% of tech volume growth in June per Nielsen, and plus 26% for Q2 as a whole. That marks ZYN's return to leading the category on both growth and market share. Sequentially, ZYN offtake volume sped up to about plus 12% growth against Q1, matching the total category. With a number of commercial programs resuming late in the quarter, the outlook is clearly encouraging as we sharpen our focus on legal edge smokers and vapers who have yet to make the switch. Q2 shipments rose 41% year over year, hitting 119 million cans. As happens with any out of stock scenario, quarterly shipments can be volatile. Getting the value chain back to proper stock levels basically wrapped up during the first half, and most of that happened in Q1; our estimate for the total net effect is roughly 40 million cans across the year, a touch under what we originally anticipated. That figure takes into account the encouraging development that retail availability is now getting close to normal, and with the scarcity premium in retail price coming down, the gap to competitors has narrowed. A key point is that sales velocity is picking up, and given the 36% growth recorded in June, that's a promising sign for the back half of the year. Since shipments are now mainly being propelled by consumer of tech, we're looking at Q3 shipment volume staying broadly in line with Q2, while allowing for the chance of a few days of adjustment to wholesaler and this inventory as things return fully to normal. Our full year US shipment target remains 800 to 840 million cans, which includes a sequential step up in Q4. Our US production capacity was increased ahead of plan, and we're now well positioned for this year and beyond. We're incredibly excited to drive ZYN and the overall nicotine pouch category potential over the coming years. Having covered Europe, Japan, and the US in some detail, let's look at the rest of the world. In most markets, both the nicotine pouch category and our multi-category presence are nascent.
Emmanuel Babeau
executiveLooking at ZYN and VIV, momentum from IQOS is something both will tap into. Adjusted in-market sales for that brand accelerated during the second quarter, reaching 19.3% growth, and those gains were broad-based, appearing in markets such as Egypt, the Philippines, and Indonesia. Of course, at this stage pouch and e-vapor volumes remain fairly minimal in those countries, which means for Q2 growth can be measured in multiples rather than percentages. Across major cities globally, that impressive IQOS growth is reflected in off-tech share gains. Strong standing in South Korea and Malaysia is equaled — and surpassed — by leading cities in Mexico, Serbia, the Middle East, and North Africa. Worldwide duty-free and travel retail keeps expanding at a strong clip too, cutting across many product segments and gaining more and more visibility. When it comes to cigarettes, the largest market globally by volume after China is Indonesia, and in Jakarta our off-tech share climbed 2.5 points versus a year earlier, reaching 7.5%. Following positive outcomes from the pilot release of Bons — our full-flavor heat-not-burn offering designed around local taste preferences — we kicked off a broader rollout not long ago. Bons is performing well in Lebanon as well. Turning now to combustibles: the segment delivered solid organic net revenue growth, up 2% in Q2 and 2.9% across H1, while Marlboro reached a post-spin category share peak of 10.7% during Q2. Q2 pricing came in at a solid 7.2%, with Indonesia, Germany, and Italy all making significant contributions, which brought H1 to 7.7% overall. We still expect pricing to moderate in H2 due to timing and comparison dynamics, but our full-year projection is now 6% to 7%. When we take pricing action, our approach is to optimize the financial contribution to the business over time, and that can naturally have an effect on volume and share performance from quarter to quarter. As discussed earlier, our combustible business is resilient, and pricing, combined with category leadership and ongoing efficiencies, drove very good gross profit growth. That performance is in line with our goal of maximizing value over time and supporting growth of our smoke-free business. That brings me to the updated guidance we have for an outstanding 2025, in which we're lifting our projection for adjusted diluted EPS for the year, both on a currency-neutral basis and over the long term. As we anticipated, our H1 organic results came in strong compared with the full-year target ranges we set. And although combustible volume trends, along with how comparisons and costs fall across the periods, turn less favorable in H2, the underlying picture stays highly encouraging; we look for continued solid momentum behind IQOS and ZYN, together with healthy pricing and a substantial gain in margin. We also anticipate additional double-digit adjusted IMS growth for HTUs, weighted toward Q4 because Q3 faces a tough comparison. Three. For the third quarter, our HTU shipment guidance is 38.5 billion to 39.5 billion, and we expect adjusted diluted EPS to grow dynamically, landing between $2.08 and $2.13. That figure reflects significant investment as well as a five-cent tailwind from currency at current exchange rates. Looking at the entire year, we still anticipate very robust organic net revenue growth, somewhere in the 6% to 8% range. Given a powerful first half on the top line in Amazon along with ongoing margin improvement, we are raising our outlook for organic operating income growth to a range of plus 11% to plus 12.5%. We're also increasing our currency neutral adjusted diluted EPS growth outlook to plus 11.5% to plus 13.5%; this reflects a modestly better effective corporate tax rate of roughly 22% to 23%, drawn from our newest evaluation of tax dynamics and market mix. We're continuing to examine what the OBBB Act US tax reform means for us. Measured in dollars, we anticipate adjusted diluted EPS growth of plus 13% to plus 15%. That figure incorporates an estimated favorable currency effect of ten cents at prevailing exchange rates, with favorable earnings translation from the broadly weaker dollar partly offset by transactional impact stemming from currency volatility, which I discussed earlier. Since we're anticipating a robust profit performance for the entire year along with solid cash conversion, our projection for operating cash flow is being lifted to around $11.5 billion based on current exchange rates, though this remains dependent on working capital needs at year end. On project capital expenditures, we now expect them to land a bit higher than what we previously estimated, at roughly $1.66 billion, largely due to extra investment in international ZYN capacity, and nearly all of that CapEx is aimed at fueling growth in smoke-free products. Moving to the balance sheet, we continue to aim for additional deleveraging throughout 2025. This keeps us on course to reach our targeted ratio of approximately two times by the close of 2026. During our last earnings call, I noted that our company operates on a global scale, with production spread across many regions and a supplier network spanning the world, including an established manufacturing footprint in the US. We feel we're in a strong position to address any possible supply chain disruptions. While the current environment remains unpredictable, at this point we don't expect any significant effect on our operations stemming from tariffs that have recently been introduced or proposed. Continuous gains in business quality are being fueled by our financial growth model, as smoke-free products add accretive value and combustibles show resilience, together producing substantial expansion on the bottom line. We remain firmly on course to hit or surpass the targets we set for the three-year period, which shows we can achieve what we consider top-tier growth among consumer packaged goods companies. Increasing adjusted diluted EPS in dollar terms remains a core goal, and it's encouraging that we achieved that during H1 and expect the same across the full year. With that, I'll close out the presentation with a few final thoughts. The first half came in exceptionally strong, which keeps us firmly on course for yet another year of solid results. As IQOS ZYN and ZYN scale up and generate synergies on both the consumer and commercial sides, our smoke-free business keeps growing more profitable. Support from fundamental strengths spanning every category—our combustible segment's durability plus the steps we've taken on pricing and cost savings—reinforces our best in class financial results. That's why we feel so sure about delivering robust, lasting growth in adjusted diluted EPS, whether we measure it in constant currency or in actual dollars. And on top of that, we continue to produce a great deal of cash, and we won't waver in our dedication to a dividend policy that keeps moving upward. As this transformation keeps delivering more growth, we're excited to continue returning value to the people who own our stock. With that, thank you, and we're ready to hear whatever questions you have. Good morning, Aurora — the floor is yours.
Gaurav Jain
analystThanks for taking my question; I have a few things to ask. First, it's about ZYN. You're indicating that the restock came in under your projection. How should we interpret that — that your outlook for upcoming growth was bigger before and has now been reduced, and not just yours, but the market's expectations were also bigger and have come down too? And because of that, the amount of restock required is smaller. Given that, when I look at your VIN volume guidance, if I treat Q3 as level with Q2, then for Q4 you'd need to hit 219 to 259 million cans. That's for the 800 to 840 guidance range, which would suggest roughly 15% to 36% growth quarter over quarter; and I recall from covering Swedish Match a few years back that Q4 typically had fewer shipping days for them. So they really didn't grow Q4 versus Q3. Could you walk me through the key pieces here?
Emmanuel Babeau
executiveCertainly, Gaurav; happy to do so. First, regarding how restocking affected things, let's stay a bit humble here; we're discussing a brand we aim to deliver 800 to 840 million cans for the year. Between wholesaler, distributor, and retailers, there are multiple weeks of inventory. I can't give you an exact figure; it's likely somewhere around, say, 6 to 7 weeks in total; and when we say it's somewhat lower, I mean it's evident that, for example, at the retail level, we had no accurate sense of what inventory stood at. So we came in somewhat under our projection. If I were to put a figure on it, it's perhaps around 10, 20 million cans beneath. Honestly, I can't be more precise than that. That amounts to a few days of sales, so it's truly minor. That's genuinely all we're discussing; and, once more, we dealt with this substantial out-of-stock situation, we went through the process of reloading, the positive news is that it's now behind us. We made certain assumptions about what restocking would involve. Okay. We were likely somewhat higher than what was actually required, but that's the situation. So I don't believe there's anything more to interpret from it. Ultimately, I think our attention should be on what truly matters, which is the strong momentum ZYN is now experiencing with full availability. In fact, June saw 36% growth in consumer uptake per Nielsen. Looking at the first 2 weeks of July, we're above 37%. My sense is that the market sits slightly above thirty nine percent. So essentially, at this point we're moving in alignment with the market. That simply demonstrates we've fully regained strong momentum, and naturally that's a very good sign for what lies ahead, since simultaneously, as I said, we're genuinely relaunching promotional, advertising, and commercial efforts across all three hundred sixty degrees, so to speak. So that, I believe, is the key point regarding the sequence. So, as you know, in my comments I pointed out that some adjustment may occur, you know, since consumers might have been purchasing ZYN with a shortage mentality, and our view is there could be some volume adjustment year over year, and there in q three. So that may affect how q three performs. And after that, we're saying there's a step up in q four. Ultimately, we're now in a situation where each quarter we're growing at a healthy pace. The second quarter's twelve percent growth compared with q one was, by a wide margin, the largest sequential quarter on quarter expansion since the first quarter of twenty twenty. Four. So we've truly returned to fresh dynamism. And we're expanding rapidly year on year, and that's what's fueling our forecast for volume growth in in in the next in in the next month.
Gaurav Jain
analystAlright, and then my follow-up is about EUTD. You mentioned a handful of remarks there, but could you walk us through it in greater depth — specifically, what do the proposals actually say regarding the various tax rates applied to NGP products? Also, is there anything new on EUTPD?
Emmanuel Babeau
executiveGaurav, I won't go into detail on that first proposal. This is the early stage of a lengthy procedure. Previously, in 2010 and 2011, roughly two years passed, as I recall, from start to finish. Plenty of debate lies ahead. I pointed out to everyone that all parties must be unanimous. So I'll hold off on commenting until there's greater clarity about what will unfold. The process has begun. Multiple stages are coming. As I mentioned before, nearly two years elapsed. Naturally, once we understand better what is truly probable, at that point we'll address what it means. During my remarks, I flagged two items that matter to us right now. First, the fact that the opening proposal does include a distinction between smoke free and combustible regarding minimum taxation. That's a significant piece. And second, it's something we're hoping gets refined. Clearly, nothing addresses illicit trade, which I believe is a genuine issue the European Union needs to confront. That's all we can offer at present.
Gaurav Jain
analystThanks a lot, and same to you.
Eric Serrano
analystExcellent, thank you.
Emmanuel Babeau
executiveGood morning. I have a few questions. To start,
Eric Serrano
analystI get that this isn't within your control. Then, moving to the international side — could you walk through what's behind the pickup in IMS and whether that can hold through the back half of the year? Thanks.
Emmanuel Babeau
executiveOf course, Eric. Starting with the US: we have nothing fresh to share regarding a possible PMTA for IQOS Illuma. Everyone can observe that the FDA is picking up its work on PMTAs again, which is encouraging. On our side — and this is publicly available — a Tobacco Product Scientific Advisory Committee meeting has now been set for the MRTP renewal on IQOS 3. A docket has also been opened for a ZYN MRTP. So several developments are underway, and that's the extent of what we currently know. Regarding the PMTA for IQOS Illuma, I have no updates. An H2 approval remains our hope, though we simultaneously recognize that the FDA's schedule and volume of work are extremely demanding. So plainly, we cannot be certain of securing this PMTA in 2025. Naturally, that could slip into 2026. On your second point, about why IQOS is accelerating — I already listed, I believe, quite a few reasons. Truly, it comes down to Europe, where the impact of the characterizing flavor ban is now fading and several markets are speeding up again. A few are delivering genuinely powerful results — I named some earlier, such as Spain, Germany, Romania, Bulgaria. It's also encouraging to watch Italy speed up once more. So I'd describe the momentum as rebuilding. Yes, there was some phasing last year in how Europe performed, yet overall we anticipate a solid H2. Beyond Europe, expect Japan to keep performing very well, and I've been discussing that trend, where we remain highly successful. Then there are all these emerging growth markets that are tremendously exciting — global travel retail being one, obviously, plus Indonesia, numerous Gulf region countries, Mexico, the Philippines. There are plenty of markets where we observe a really attractive growth trajectory and upside for IQOS. And within these emerging growth markets, momentum is, I'd say, steadily accumulating.
Eric Serrano
analystExcellent, and I just have a single quick follow-up regarding Combust. Your volumes fell by 1.5%, or rather, merely 1.5%, even with the headwinds you mentioned in Turkey and Indonesia. Given that you folks have been quite candid ever since last year about anticipating that combustible volumes would return to declining in 2025, was that in fact somewhat better than you had anticipated?
Emmanuel Babeau
executiveYou're correct. At present, on a global basis, as we state, our goal for this year is to land at approximately minus 2% regarding shipments. I have had the chance to express that quite plainly on earlier occasions. We hold the view that we will return to what we regard as the long-term pattern for the combustible segment, namely a low single digit reduction. I cannot specify precisely which variety of low single digit, yet that certainly is a pattern. One we anticipate going forward. Yes, naturally. A nation that prohibits smoke free products may exert some influence on this low single digit reduction, but even so, that remains a pattern. That is what we observed during Q2. Mostly consistent with what we had expected, and that is what we anticipate for H2, given this Turkey effect, which is somewhat of a transitional matter set to affect H2 in particular. Apart from that, I believe we are steadily returning to what we termed a normal long-term pattern for combustible.
Eric Serrano
analystFantastic. Many thanks, Emmanuel. I'll relay that. Appreciate it. Thanks.
Eric Serrano
analystthe second quarter, plus some beneficial impact from the tax rate.
Emmanuel Babeau
executiveYes. I believe, as you're aware, when examining this, naturally there are various factors capable of skewing how things appear from one quarter to the next, or between the second half and the first half. What mattered to us was making sure everyone grasps that actually, the trajectory for smoke free during Q2 is actually stronger than what we saw in Q1. And Q1 had already been quite strong. Yet in Q2, what we witnessed was IQOS in-market sales speeding up. And, as you know, it's good to be back to good double-digit expansion — a really strong and really robust reacceleration for Zine within the US. Naturally, in other markets, ZYN alongside VIVA are expanding extremely quickly. But Q2, in truth, represents a really solid step up for our smoke free operation, and that's completely apparent in the figures we posted. Turning to H2, we actually anticipate that these highly robust dynamics observed in H2 for smoke free will carry on. Therefore IQOS should keep expanding at a double-digit rate when it comes to adjusted IMS; with availability no longer being a problem for ZYN in the US, we anticipate that this really powerful acceleration for ZYN in America will persist. Once more, I mentioned the 37% expansion during the opening two weeks of July. So for ZYN in the US, H2 is off to a solid start. Thus this momentum hasn't shifted, and we anticipate it staying really robust. What will certainly be less advantageous is how combustibles are trending; we were nearly level, down 0.3% in volume, across H1, and we anticipate a decline of 3% to 4%. I've already walked through what's driving that. Even so, we anticipate gross profit growth for combustibles, though naturally at a reduced level relative to H1. So that's among the causes behind the differing performance we can anticipate in H2 compared with H1. Then there are various phasing factors relating to smoke free that have nothing to do with performance; rather, they stem from comparison bases or certain one-off occurrences. Looking at IQOS, Q1 included that one billion stick shipment, which we will offset during Q4; naturally, that helps H1 and hurts H2. We enjoyed extremely helpful comparables in H1 thanks to device sales accelerating last year, which kept boosting profit and margin; that won't be present in the latter portion of the year, making that yet another factor. And then there's the restocking, which helped H1. Naturally, it won't be helping H2. Yet I'd say that's genuinely the foundation for the guidance, and provided you factor in each piece I've just described, you'll grasp the dynamic correctly. Hopefully that answers your question.
Eric Serrano
analystThat's quite useful.
Matt Smith
analystNow, for my next question — in those markets where you're raising prices, what effect is that having on volume and on bringing in new users compared with what you'd anticipated? And does that shift how you view the pricing opportunity in the HTU business as time goes on? Thanks — that's all from me.
Emmanuel Babeau
executiveAbsolutely, Matt. What we're aiming for is to avoid letting a price hike hurt sales volumes for IQOS and ZYN, since we've highlighted how strong the volume increase is—driven by greater revenue per unit and better margins. So naturally, the goal is to fully maximize volume; however, as we expand the brand's franchise and its strength, raising prices does bring a benefit. That works as long as volume isn't affected; I believe that's the proper balance we're after—growing volume, yet we definitely don't want to alter the volume trajectory because of pricing. So yes to price increases, but only if they don't significantly disrupt the volume path. That's our approach, and we'll keep doing it.
Bonnie Herzog
analystThanks. Hello there, Emmanuel.
Emmanuel Babeau
executiveHey. I had a couple of additional questions regarding ZYN.
Bonnie Herzog
analystTaking into account all the points you raised and, you know, the conditions you're observing out there in the market, ought we to conclude that the bottom end of your shipment guidance for the full year is the more plausible outcome? I suppose what I'm attempting to get at is whether the top end is even achievable in your view; and then could you bring us up to date on, you know, your capacity and what the situation is right now? And at what point it will go up.
Emmanuel Babeau
executiveAlright, so naturally, when we provide that range, our belief is that we can close out the year inside it—at any given point within that range. We've given eight hundred to eight hundred forty million. Obviously, the reality that there's this ten to twenty million less restocking than what we perhaps anticipated—I mean, that does have an effect. But ultimately, as you can see, the relaunch of IQOS has the potential to be quite strong. I mean, thirty six, thirty seven percent. We're bringing commercial activity and advertising back. So what the growth profile will look like for H2, we don't know. That's the reason we remain at ease with the eight hundred to eight hundred and forty million range; regarding capacity, we can state that as of today, we've been constructing a comfortable level of capacity to handle every sort of highly dynamic growth scenario going forward, and so we feel at ease for the quarters ahead.
Bonnie Herzog
analystAll right. And maybe one more question, since you brought up a point I was also curious about — namely, at this stage, I suppose you're basically no longer out of inventory, or you're able to fulfill whatever demand comes in. In what ways does that shift your approach when it comes to Zen, and when it comes to your pricing and promotions? Do you think you'll perhaps become somewhat more aggressive, trying to potentially expand ZYN at a quicker pace and capture additional market share? What's your thinking on that?
Emmanuel Babeau
executiveAppreciate it. Yes, yes, absolutely, Bunny. So you've got it right. Like I mentioned, our approach is to pull every lever available to drive ZYN's expansion as much as possible, and we're doing that in a completely different set of circumstances since supply is now fully there. For a lot of months and a lot of quarters, we held ourselves back from bringing in new consumers, because we understood we simply couldn't meet the demand coming from new users. That translated into restrained efforts, I'd say, on every front. That covers pricing as well as marketing work. So we will kick off regular operations again, and that will definitely involve heavier promotional push. Right? Our promotional level sits far below what any rival brand does, and my sense is that won't change. Still, that doesn't rule out the possibility of raising how much promotion we do. There will also certainly be advertising plus commercial efforts at the point of sales, where we now need to ramp things up given that the product can be supplied. On top of that comes continuing to build the brand franchise, along with all those iconic elements tied to the ZYN brand and the fine using campaign. So every lever gets pulled to ensure we provide the strongest possible backing for ZYN.
Bonnie Herzog
analystOkay. Thank you. I'll pass it on.
Emmanuel Babeau
executiveThanks.
Faham Baig
analystHey there, Emmanuel. Thanks for fielding my questions. Honestly, the responses you gave were quite comprehensive.
Faham Baig
analystThe gap in gross margin between combustibles and smoke-free products got smaller. And it's possible smoke-free even saw its gross margin dip a bit.
Matt Smith
analystmoved down from Q1 to Q2. Perhaps you could elaborate on a few of the factors driving that, and also what you anticipate regarding the gross margin gap in the coming two quarters. Then my second question is likely straightforward, but could you kindly remind us of your FX hedge rates for this year — euro, Japanese yen, plus any additional currencies you happen to hedge. Thanks.
Emmanuel Babeau
executiveYeah, Sam. Regarding how gross margin is developing — you're paying attention to that comma, right? Because actually, in both Q1 and Q2, we're sitting at roughly a 70% gross margin rate. Naturally, the ZYN mix, or rather, how significant the device is, can influence things. But overall, consistent with what we communicated following Q1, we have a small prebinder that sits at approximately — it doesn't have to be exactly that, it could be slightly lower, but approximately 70% gross margin. And my expectation is that H2 won't differ in any very material way. Alright? So I'm not claiming it will definitely land at 70, but I believe we're in the ballpark of this range, where Smokree enjoys a really attractive gross margin rate. That's above combustible, and you picked up on the fact that this gap has narrowed somewhat; it remains substantial. I mean, 4.5 for the entire H1. And that's down to CC having improved somewhat, which reflects price and mix of the combustible sales during the quarter. So when I consider the latter half of the year, I'd really want to stress that margin improvement in the smoke free business mattered a great deal in H1, since we were up against easy comps thanks to lots of Illuma device sales a year ago when we were launching Elooma I. Essentially, that situation no longer applies in HQ. So the easy comps aren't there anymore, and as a result, just as I mentioned, expect margin on smoke free to remain high and expect, naturally, the year-on-year progress to shrink, because we're up against a higher margin a year ago in the smoke free business. On combustible, I believe we stated that we aim to raise the gross margin too, and that holds true for
Eric Serrano
analystRegarding the second half, then.
Emmanuel Babeau
executiveLet me start with currency matters, and I won't go over that again, since honestly I haven't checked precisely where things stand most recently. The reason I'd been covering it is that, as I recall, following Q1 we felt it useful to show what our situation looked like when it came to hedging exchange rates — though doing that on every occasion isn't my plan. Just so that's clear.
Faham Baig
analystAll right. Appreciate it, Emmanuel. Thanks a lot.
Callum Elliott
analystExcellent. Thanks so much for asking that.
Matt Smith
analystEmmanuel.
Callum Elliott
analystHello, Emmanuel. Let me start with a question about Aviv, if you don't mind. For quite a few years, my impression is that your team showed considerable hesitation about pushing heavily into the e vapor segment, pointing to weaker customer retention there and the effect that weaker retention had on gross margins.
Faham Baig
analystAt your Europe event, we clearly picked up some of this
Callum Elliott
analystone month back regarding the growing focus on a three category strategy and the benefits that come from having all three categories work together.
Matt Smith
analystWhen you're engaged across all three areas simultaneously. Yeah, I suppose what I'm really asking is what has shifted during the last year or two to
Callum Elliott
analystWhat's driving this strategy of expanding into three categories? And specifically, I think you mentioned in the release the better gross margin you're observing that you might
Emmanuel Babeau
executiveparticularly. I'm just curious—I doubt you'll give me a figure, but is there anything qualitative you can tell us about what that means? Of course, Calum. So yes, I believe it was covered quite thoroughly at our European day. So I'm sure I won't provide that same level of detail. My first point would be to say,
Matt Smith
analystI
Emmanuel Babeau
executiverest assured, we understand exactly where our focus needs to be. Our top objective, above all else, is expanding IQOS. Right? That brand is our brightest star. It's the one offering the greatest opportunity; it's the one delivering our strongest profitability. Absolutely. Xyng might eventually reach that same tier, though naturally, in terms of volume, it remains quite tiny at present across most of the market. So that's a matter for down the road. You should view Veeve as a struggling brand within our lineup. Right. There's value in pursuing a multi-category strategy. I won't go through all the details we shared regarding Europe. The point is that certain consumers genuinely favor staying within just one category, under a single brand. Then again, at times, you know, some smokers want to quit smoking entirely. That only happens if they transition to multiple smoke reported; that's precisely when we need to provide multiple smoke free categories, and that's the role this plays under those conditions. Naturally, we're directing our focus toward areas where we're confident a profitable business can be built. And that is, naturally, an extremely, extremely vital prerequisite for growing these. I won't give you an exact gross margin figure for these, but I can share that it rose by over 10 percentage points compared with the start of 2025. So its profitability is climbing very quickly; and we think that given the right loyalty, the VIVE business stands a chance of achieving profitability comparable to the business. Collectively, you need the right loyalty, yet what we're observing currently in markets where we're building this appears to indicate we can reach that degree of repurchase and loyalty. So it's a somewhat brief recap, but those are the requirements for us to grow these; and and that's what sits behind our Veev progression.
Callum Elliott
analystI just want to clarify something. When you mention profitability at a similar level to FIGRATS, are you referring to the margin as a percentage or the margin per unit?
Emmanuel Babeau
executiveIn terms of gross margin on revenue. Gross margin. Understood. As a percentage.
Callum Elliott
analystAll right, that's great. And my follow-up relates to ZYN — it kind of sits where Garev's and Bonnie's earlier questions overlapped. Clearly, what you've described is a growth trajectory running around 27% year over year in Q3. Though it may be somewhat affected — it sounds like you're pointing to some destocking — and then the guidance for the whole year suggests a reacceleration in Q4. What I'm wondering is how the commercial work feeds into that pickup you're projecting for the fourth quarter, and how much confidence you have that, as you ramp those
Faham Baig
analystefforts back up,
Callum Elliott
analystthe way you did previously — right, back when you acquired this business from Swedish Match — that it fueled a speedup at that time. But now, as you push into these efforts once more, the ones you'd sort of pulled back from during the supply chain issues — do you really have the capability to reignite that acceleration? How sure are you of that? And does the pattern of these efforts account for the pattern between Q3 and Q4?
Emmanuel Babeau
executiveWell. I believe I've already, in a way, given whatever response I'm able to give. So yes, in fact. That indicates a highly dynamic latter half of the year. Once more, the growth level in consumer of tech during June and early July points in a direction largely consistent with that growth, and this is at a moment when, as I mentioned, we haven't yet completely relaunched all the commercial slash marketing efforts. So we're hopeful this will deliver an additional lift to growth. There isn't much more I can offer at this point. I think the figures sit there on the table, publicly available, and anyone can grasp the target we've set.
Callum Elliott
analystPerhaps I could add one more question here. How fast are you able to get those commercial efforts going again? It really looks like the speed at which you had to replenish stock caught you somewhat off guard. So how fast can you switch it back on?
Emmanuel Babeau
executiveYeah, well, obviously this isn't something that occurs within just a few weeks; it happens step by step. Not all of it occurs simultaneously. So right now the team in the US is extremely occupied, gradually bringing everything back up. Still, you're correct. It's comparable to, you know, rebuilding an engine. And reaching top speed with that engine is going to require a certain amount of time. Naturally, I won't go into more detail, as you can appreciate, but this is something that will unfold progressively over the course of Q3.
Callum Elliott
analystOkay, many thanks.
Faham Baig
analystThank you. Thank you.
Gerald Pascarelli
analystGreat. Thanks so much for that question. The majority of them have already been addressed, though I did want to revisit the topic of currency. Could you give us some detail regarding precisely what happened during the quarter? You failed to receive the advantage you had been steering us toward for 2Q. And that holds true even though the dollar got weaker as the quarter went on. So the way I see it, the hope was that on top of a raise to underlying EPS, we'd have seen your adjusted EPS gain even more simply because the currency outlook had grown more favorable. So, not after specifics on your particular hedges or anything of that nature, but perhaps just a bit of color or some thinking on how we ought to approach the currency tailwind should we keep watching this dollar weaken through the back half of the year? Any color on that would be terrific. Thank you.
Emmanuel Babeau
executiveAbsolutely, Joel. Honestly, something folks might not always be aware of is that compared with the $0.10 we're projecting, we're at roughly $0.04, which is under what consensus had anticipated. I'd say the main driver is the Swiss franc. That's true both because of the adverse effect it creates, since our cost exposure to Switzerland is substantial. As all of you are aware, we But it's also because of intercompany flows — when volatility is high and the Swiss franc has surged considerably against other currencies, by the time the period closes, that produces certain transactional losses. So the impact there is considerable. And in fact, when I examine what's behind this estimated $0.10 impact at the prevailing rate, the Swiss franc is actually offsetting a big portion of the benefit we get. On the euro, just so everyone can follow; so it's a very substantial adverse effect.
Gerald Pascarelli
analystGot it. Thank you very much.
Emmanuel Babeau
executiveThank you.
Priya Ohri-Gupta
analystHello there, and good morning to everyone. I really appreciate the chance to ask something. Emmanuel, I was hoping you might take us through the working capital component within free cash flow. From what the figures suggest, it seems like that may have come in somewhat softer on a seasonal basis compared with what we typically observe during the second quarter. Would you say that's mostly because of what's happening with IQOS, or are there other factors at play? And after that, our expectation is that the bulk of it will turn around once we move through the latter half of the year.
Emmanuel Babeau
executiveAbsolutely, Priya. When you examine where we stand at the midpoint of H1 and compare that with the same period a year ago, the cash generation is indeed weaker. The main driver there is the duty payment we completed in Germany, along with the last installment tied to the job act in the US. Taken together, those two items add up to well over $1 billion, and that truly accounts for the largest piece of it. Apart from that, sure, we might have built up some inventory temporarily — supply chain factors naturally come into play in various spots. Regulatory restrictions can also crop up. Still, as far as working capital goes for the full year, aside from those two items I just referenced, nothing unusual should be anticipated.
Priya Ohri-Gupta
analystAll right, that clears things up. And just to take care of one administrative matter, how much did you spend on capital expenditures during the quarter?
Emmanuel Babeau
executiveI don't believe we break that out on a quarterly basis. So I won't provide you with that figure. My recollection is that we mentioned 1.6 billion dollars for the full year, though we don't divide it up quarter by quarter. All right. I really appreciate it.
Gaurav Jain
analystThanks.
James Bushnell
executiveAppreciate it, everyone. That brings today's call to an end. Thanks for being with us. Should anything else come up, feel free to reach out to the investor relations team. Thanks once more, and enjoy the rest of your day. Thank you. Talk to you soon.
Operator
operatorThis concludes today's conference call. Thank you for participating. You may now disconnect.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Philip Morris International Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Philip Morris International Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Philip Morris International Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.